Suchergebnisse - "Liou, Theodore G"

PubPharm (7)

1

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data

enthalten in: PloS one | 2023

von McGarry, L. | Bhaiwala, Z. | Lopez, A. | +4

2

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND) : an open-label extension study

enthalten in: The Lancet. Respiratory medicine | 2021

von Flume, P. | Biner, R. | Downey, D. | +118

ErratumIn: Lancet Respir Med. 2021 Apr;9(4):e38. - PMID 33636124

3

The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein : Its Role and Function in Extrapulmonary Disease

enthalten in: Chest | 2019

von Liou, T.

4

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor

enthalten in: Therapeutic advances in respiratory disease | 2019

von Rubin, J. | O'Callaghan, L. | Pelligra, C. | +5

5

Sleep Phase Delay in Cystic Fibrosis : A Potential New Manifestation of Cystic Fibrosis Transmembrane Regulator Dysfunction

enthalten in: Chest | 2017

von Jensen, J. | Jones, C. | Kartsonaki, C. | +3

6

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

enthalten in: Chest | 2012

von Flume, P. | Liou, T. | Borowitz, D. | +5

7

Carrier screening, incidence of cystic fibrosis, and difficult decisions

enthalten in: JAMA | 2009

von Liou, T. | Rubenstein, R.

CommentOn: JAMA. 2009 Dec 16;302(23):2573-9. - PMID 20009057

1
[1]